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Budding yeast Saccharomyces cerevisiae has proven to be a valuable model organism for studying fundamental cellular processes across the
eukaryotic kingdom including man. In this respect, complementation assays, in which the yeast protein is replaced by a homologous protein from
another organism, have been very instructive. A newer trend is to use the yeast cell factory as a toolbox to understand cellular processes controlled
by proteins for which the yeast lacks functional counterparts. An increasing number of studies have indicated that S. cerevisiae is a suitable model
system to decipher molecular mechanisms involved in a variety of neurodegenerative disorders caused by aberrant protein folding. Here we review
the current knowledge gained by the use of so-called humanized yeasts in the field of Huntington's, Parkinson's and Alzheimer's diseases.
© 2008 Elsevier B.V. All rights reserved.Keywords: Neurodegenerative disease; Huntington; Parkinson; Alzheimer; Yeast; Protein folding1. Introduction
The baker's yeast Saccharomyces cerevisiae has proven its
utility for clarifying fundamental cellular and molecular pro-
cesses. Apart from being a useful toolbox to study both physical
and genetic interactions between proteins, this unicellular
eukaryote allowed to gain insight in basic cellular mechanisms
such as DNA replication, recombination, cell division, protein
turnover and vesicular trafficking. It also contributed to our
understanding of nutrient- or stress-induced signal transduction,
the coordinated regulation of metabolic and cellular adaptations,
the cell cycle progression and mechanisms involved in longevity
and cell death. The general picture that evolved from these studies
shows that key cellular processes are well conserved between
yeast and higher eukaryotes, including humans. In addition, upon
publication of the yeast and human genomes it became clear⁎ Corresponding author. Tel.: +32 16 321516; fax: +32 16 321967.
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doi:10.1016/j.bbamcr.2008.01.020that approximately 31% of the yeast genes have a mammalian
homologue and an additional 30% of yeast genes show domain
similarity [1]. Consistently, about 30% of the genes known to
be involved in human diseases may have a yeast orthologue
[2,3]. These observations paved the way for a rebirth of the use
of yeast in medicinal and medical research. While initial expe-
riments focused on classical complementation assays to eluci-
date the biological role of human proteins that have a yeast
counterpart, a new trend brings the development of yeast cell-
based assays or so-called humanized yeast systems to study
functional aspects of proteins that do not have a yeast
homologue [4].
In this review, we focus on recent contributions made by
yeast systems to resolve fundamental questions on the patho-
genic role of human proteins in neurodegenerative diseases. To
date, several neurological disorders have been modeled in yeast.
However, only for Huntington's, Parkinson's and Alzheimer's
disease did this consisted of humanized model systems, i.e.
expression of human proteins that lack a yeast orthologue
(Table 1). The data obtained with these humanized yeast models
demonstrate that despite the lack of a nervous system in yeast,
Table 1
Human neurological disorders modeled in yeast
Disease Protein
involved
Yeast
orthologues
References
HD and PolyQ disorders Huntingtin No This paper
PD and synucleinopathies α-Synuclein No This paper
AD and tauopathies Tau and APP No This paper
Amyotrophic Lateral Sclerosis
(ALS)
SOD-1 Yes [166]
Friedreich's Ataxia Frataxin Yes [167]
Batten disease CLN3 and PPT1 Yes [168]
Niemann–Pick disease NPC1 Yes [169]
Hereditary Spastic Paraplegia
(HSP)
AAA-proteases Yes [170]
HD, Huntington's disease; PD, Parkinson's disease; AD, Alzheimer's disease.
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made (Table 2).
2. Humanized yeast models for Huntington's disease and
PolyQ disorders
2.1. Characteristics ofHuntington's disease and toxicmechanisms
in mammalian cells
Huntington's disease (HD) is an autosomal dominant neu-
rodegenerative disorder mainly affecting the striatum and cortex
of the brain. The disease has a prevalence rate of 5 to 10 persons
per 100,000 and is characterized by uncontrolled movements,
psychiatric disturbances and cognitive impairments that begin
in mid-life and progress to death within 10–20 years of onset.
The genetic defect underlying HD is an expansion of a CAG
trinucleotide repeat encoding a polyglutamine domain (polyQ)
within the N-terminal end of the Huntingtin protein (Htt). In
unaffected individuals, the CAG-repeat number in Htt varies
between 11 and 34, while in HD this number increases to more
than 35 repeats.
Htt is a multidomain protein in which the N-terminal half
consists of the polyQ stretch followed by a proline-rich domain
and ten HEAT repeats, a characteristic protein–protein interaction
motif. The protein plays an essential role in cell survival and is
distributed in various subcellular regions where it is believed to
fulfill a scaffolding function [5]. Htt was indeed found to interact
via its N-terminal segment with a variety of proteins involved in
intracellular trafficking, endocytosis, metabolism, and gene
transcription [6–8]. Notably, several of the Htt interaction part-
ners have homologous counterparts in yeast [6,9].
Because of the essential function of Htt, the CAG expansion
is often described as a loss-of-function alteration. Nonetheless,
the expansion also confers a newly gained toxic function re-
sulting in nuclear and cytoplasmic aggregation of the mutated
protein and its proteolytic N-terminal fragments that encompass
the polyQ domain [10]. It has been proposed that this toxic gain-
of-function reflects unusual conformational changes that facil-
itate oligomer formation and aggregation, as well as altered
protein–protein interactions [7,11–13]. However, the mechan-
isms underlying the neuronal death induced by polyQ expan-sions remain elusive. Due to the multitude of Htt-interactions,
several scenarios have been proposed. Aggregation of Htt was
proposed to sequester important transcription factors, such as the
CREB-binding protein, CBP, or the neuron-restrictive silencing
factor, REST-NRSF, thereby altering the transcription profile in
susceptible neurons [10,14]. Others proposed that cell death
induced by Htt aggregation mirrors the requirement of Htt for
vesicular trafficking, a hypothesis that is reinforced by the recent
discovery of a membrane targeting sequence at the very N-
terminus and a palmitoylation site at cysteine 214 in Htt [15,16].
An anti-apoptotic function has also been ascribed to Htt and
apart from aggregation-induced indirect influences triggering
oxidative stress and mitochondrial dysfunction, the protein may
also exert a more direct effect since Htt with an expanded
polyQ domain is unable to bind to HIP-1, a protein that contains
a death box and can activate caspase-8 when released from Htt
[17–19].
In addition to the possibility that several pathways may trigger
Htt-related cell death, it is still a matter of debate whether soluble
oligomers and protofibrils, or the aggregated polyQ peptides are
the inducers of toxicity [20,21]. Accumulating evidence favors a
toxic role of prefibrillar intermediates and suggests that the fi-
brillar aggregates are inert and may even have a cytoprotective
function. One example related to the latter is a report showing that
the mammalian target of rapamycin, mTOR, is sequestered into
Htt aggregates, which would lower mTOR activity and thereby
induce autophagy, a known clearance pathway for toxic Htt
fragments [22].
2.2. Yeastmodels forHtt-induced toxicity and apoptotic cell death
Several research groups have developed yeast models to study
the folding and behavior of proteins with an expanded polyQ
domain. These yeast systems usually express polyQ N-terminal
peptides of human Htt as fusions or tagged proteins. The first
models already demonstrated that heterologous expression of Htt
results in a polyQ length-dependent aggregation in yeast [23–25].
Interestingly, in only one of these models the aggregation of Htt-
derived fragments triggers toxicity and reduced growth. The
reason for this is dual. On one hand, it was shown that toxicity
upon expression and aggregation of expanded polyQ peptides in
yeast requires the protein Rnq1 in its prion conformation [25]. As
such, this observation indicated that the aggregation of Htt
fragments is not toxic per se and it also suggested that the ag-
gregation of polyQ peptides and of the prion form of Rnq1 share
similar features that would allow interference with each other.
However, so far no evidence for mixed co-aggregation of polyQ
fragments and prions has been provided. Nonetheless, aggregates
ofHtt and prions appear to have a commonβ-helical amyloid core
structure [26,27] and it has been shown that aggregated expanded
polyQ peptides do promote prion formation of Sup35 in yeast
[28]. Moreover, a very recently performed compound screen in a
zebrafish model of HD led to the identification of two anti-prion
compounds as efficient inhibitors of polyQ aggregation [29]. On
the other hand, toxicity of aggregated polyQ peptides in yeast
strongly depends on the sequence context of the polyQ domain
[30]. Particularly, the presence of the endogenous proline-rich
Table 2
Selected articles
Topic Description References
Background on the disease
General Protein misfolding and neurodegenerative diseases [21]
Role of oxidative stress and mitochondrial dysfunction in neurodegeneration [171]
HD and PolyQ disorders Molecular pathogenesis of HD and other trinucleotide repeat disorders [10,59]
PD and synucleinopathies Genetics and pathways underlying PD [63,68,75]
AD and tauopathies Genetic components of AD and the role of protein tau in neurodegeneration [128,142]
Yeast models
General Yeast as a tool for medical and medicinal research [4]
Advantages of yeast-based drug discovery screenings [165]
The apoptotic machinery in yeast [164]
Huntington models Molecular determinants for toxicity of expanded polyQ peptides in yeast [31]
Expression of toxic polyQ peptides and apoptotic cell death in yeast [35]
Parkinson models Expression of α-syn and blockage of ER-to-Golgi vesicular traffic [104]
Functional mitochondria and α-syn toxicity in ageing yeast [121]
Alzheimer models Hyper-phosphorylation, conformational changes and aggregation of protein tau in yeast [135]
Yeast-based reporter system to monitor the oligomerization of Aβ42-fusions [162]
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proteins, evenwhen present in trans on a co-expressed Htt variant
with a polyQ domain of normal length [30–32]. This suggests that
the proline-rich domain may serve to recruit other proteins that
shield Htt from perturbing essential cellular functions.
Recent studies connected Htt-toxicity to apoptotic cell death.
Similar to neurons [33], expression of expanded polyQ peptides
in yeast was reported to reduce the respiratory capacity due to
impairment of the mitochondrial respiratory chain complexes II
and III [34]. Consistently, aggregation of polyQ peptides in
yeast coincided with apoptotic changes in mitochondria, cas-
pase activation, nuclear DNA fragmentation and apoptotic cell
death [35]. This study also showed the accumulation of the
expanded polyQ peptides in the nucleus at longer times after
induction and interestingly, this nuclear translocation required
the functional yeast metacaspase Yca1 [35].
Both toxic and nontoxic polyQ constructs were used to iden-
tify proteins that influence Htt aggregation and toxicity in yeast.
Several groups showed that aggregation and toxicity of expanded
polyQ peptides depends on the activities of the molecular chap-
erone Hsp104 and family members of Hsp70 and Hsp40
[23,25,32,36,37]. This observation is particularly interesting be-
cause Hsp104 is known to recycle proteins from previously
formed aggregates, a function it exerts with the assistance of
the Hsp70 protein, Ssa1, and the Hsp40 protein, Ydj1 [38]. In
agreement, the overexpression of Hsp104 and Ssa1 were found to
completely suppress the growth defect associated with expression
of toxic polyQ peptides in yeast [32,37]. Although mammalian
cells do not encode for an Hsp104 homologue, it is now
established that expression of yeast Hsp104 allows for relief of
polyQ aggregation and toxicity in mammalian cells as well as in
neurons of transgenic mice and rat models of Huntington's
disease [39–41]. Moreover, expression of the yeast Hsp104
protein in human leukemic T-cells inhibited heat shock-induced
apoptotic signaling [42]. So far, the influence of Hsp104 and its
co-chaperones on Htt-induced apoptosis in yeast has not been
studied. However, Hsp104 in yeast was reported to be required for
replicative life span extension induced by a transient nonlethalheat shock [43] as well as for conformational repair of heat-
denatured proteins in the endoplasmic reticulum (ER), which
would otherwise cause a sustained unfolded protein response
(UPR), oxidative stress and cell death [44–46]. Trehalose, which
in concert to Hsp104 allows yeast cells to acquire stress tolerance,
is also involved in conformational repair of heat-denatured pro-
teins in the ER [47]. As such, it does not come as a surprise that
oral administration of this disaccharide to transgenic mice or
expression of the bacterial trehalose synthase genes in mamma-
lian cells not only reduced the number of polyQ aggregates but
also exerted beneficial effects on cell viability and life span
[48,49]. Most recently, trehalose was shown to act through
activation of autophagy in a mTOR-independent manner [50].
Consistent with the observation described above that polyQ
fragments of normal length interfere with the toxicity of ex-
panded polyQ peptides, other glutamine-rich proteins also affect
polyQ toxicity and are able to convert toxic polyQ peptides into
nontoxic ones and vice versa [31]. Interestingly, the glutamine-
rich proteins used in this study are not essential for yeast viability
and in case the proteins aggregated themselves when over-
expressed, the aggregates were not toxic. Hence, the intercon-
version of a nontoxic to toxic polyQ aggregate cannot solely be
explained by sequestration of the glutamine-rich proteins, but
must involve other factors and mechanisms.
The yeast models also allowed establishing a connection with
endocytosis. In wild type cells, polyQ aggregation led to a rapid
cessation of endocytosis, while in mutants affected in early en-
docytic events, polyQ toxicity is enhanced [51]. A recent follow-
up study proposes that the endocytic machinery, at steps of
maturation of the forming endocytic vesicle, is itself involved in
the process leading to aggregation of polyQ peptides in yeast as
well as in mammalian cells [52].
2.3. Yeast-based screenings to identify Htt-toxicity modifier
proteins and chemicals
Undoubtedly, the power of yeast lies within its versatility to
perform genomic screenings (Fig. 1). Two such screenings have
Fig. 1. Global strategies to identify putative targets and lead compounds. A. Synthetic growth-phenotype screening using the genome-wide collection of viable yeast
deletion mutants. In this collection, each yeast open reading frame (ORF) has been replaced with a cassette containing unique tags and the selectable marker gene
KanMX, which confers geneticin resistance. After transformation of the whole collection and the wild type strain with a plasmid allowing for inducible expression of
the (toxic) human protein, e.g. Htt, the transformants are grown under non-permissive and permissive conditions. Then, the growth ratios are calculated and a
comparison is made relative to the growth ratio obtained for the wild type strain. Mutants are selected that display reduced or enhanced growth as compared to the
wild type strain specifically under permissive conditions. This synthetic phenotype suggests a functional relationship between the human protein under investigation
and the yeast protein that is absent in the mutant. B. Chemical compound or cDNA screenings can be performed in the wild type or mutant strains using a similar
strategy as described above. In this case, chemicals or cDNAs are selected that improve or reduce growth only in cells expressing the toxic human protein under
investigation. A compound or a cDNA is considered false positive or negative if it also affects growth to a similar extent in cells that do not express the protein under
investigation.
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constructs were used to transform the collection of 4850 haploid
deletion strains and select mutants with enhanced toxicity [53].
This yielded 52 mutants that, based on their deficiency, revealed
a specific enrichment of the functional categories of protein
folding and the ubiquitin–proteasome system (UPS) as well as
stress response, thereby confirming some of the data described
above. Interestingly, this screen also identified strains lacking
proteins required for the redox/ROS stress response in yeast,
such as glutathione synthase, Gsh2 and the flavohemoglobin,
Yhb1. These proteins are known to be induced under condi-
tions that challenge the normal mitochondrial function [54,55].
Hence, in the absence of this defensive response, the otherwise
inert polyQ aggregates appear to become toxic. This suggests
that the mere presence of nontoxic polyQ aggregates in wild
type cells already triggers an increased oxidative stress but to alevel that can still be handled by the cellular defense mech-
anisms. The second genomic screening made use of a toxic
expanded polyQ construct and was aiming to identify yeast
mutants with reduced toxicity [56]. Twenty-eight strains were
identified and interestingly, most of them still contained the
polyQ aggregates despite the suppression of toxicity. This is
again consistent with the observation of polyQ aggregates not
being sufficient to induce a high level of toxicity. The functional
categories that were enriched in this screening included ve-
sicular traffic and vacuolar protein sorting, transcription regu-
lation and known or putative yeast prions. Once more, this is in
line with data described above. Of particular interest was the
identification of the kynurenine 3-monooxygenase, Bna4, in
this screen. This enzyme functions in the kynurenine pathway,
which is a well conserved route for tryptophan degradation and
synthesis of NAD+ in eukaryotes. Imbalances in the kynurenine
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in animal HD models and HD patients [57]. Similarly, increased
intermediate kynurenine pathway metabolites and enhanced ROS
levels were observed upon expression of toxic polyQ peptides in
wild type yeast cells, but not in cells carrying a BNA4 deletion or
cells treated with Ro 61-8048, a pharmacological inhibitor of the
mammalian kynurenine 3-monooxygenase [56]. This confirms
the conservation of the mechanism linking polyQ toxicity to the
kynurenine pathway and the generation of ROS between yeast,
mammalian cells and individuals with HD.
In addition to genetic screenings, the yeast models have been
used as a cell-based high-throughput screening system to find
chemical compounds that inhibit polyQ aggregation and
toxicity. This led to the identification of a lead compound that
is a structural analog of kynurenine 3-monooxygenase inhibitor
Ro 61-8048 [58]. Although identified in yeast, this drug also
suppresses neurodegeneration in a fly model for HD.
2.4. Other PolyQ disorders
To date, several polyglutamine diseases have been described
and the expansion of CAG repeats has been documented in genes
such as the androgen receptor, which causes Spinobulbar
Muscular Atrophy also known as Kennedy Disease, atrophin-1,
which is linked to Dentatorubral-Pallidoluysian Atrophy or
DRPLA, and several ataxin genes, which underlie several types
of Spinocerebellar Ataxias [59]. Hence, it is clear that progress
made in yeast on deciphering the molecular basis of HDwill have
a direct impact on our understanding of the disease mechanisms
involved in these other PolyQ disorders as well. Finally, it should
bementioned that apart from studies linking aggregation of polyQ
peptides to toxicity as described above, the yeast system is ad-
ditionally used to elucidate themechanisms that lead to expansion
of trinucleotide repeats [60,61].
3. Humanized yeast models for Parkinson's disease
and synucleinopathies
3.1. Pathogenesis and genetics of Parkinson's disease
Parkinson's disease (PD) is the second most common neu-
rodegenerative disease with an age-associated prevalence of
approximately 1.6% at 65 years and 4–5% at the age of 85. The
disease is clinically characterized by motor deficits such as
resting tremor, rigidity, bradykinesia and postural instability.
The neuropathological hallmark of PD consists of a progressive
degeneration of dopaminergic neurons of the substantia nigra
pars compacta and the presence of eosinophilic cytoplasmic
inclusions called Lewy bodies (LBs) and Lewy neurites [62].
Although environmental factors have been implicated in
the development of the disease, accumulating evidence shows
that different genetic factors are involved. Tremendous progress
has been made over the last few years in the identification of
genes underlying rare familial forms of PD. So far, at least 6
genes have clearly been linked to familial PD. Mutations in α-
synuclein (α-syn) and LRRK2/dardarin cause autosomal domi-
nant forms of PD, while mutations in parkin, DJ-1, PINK1 andATP13A2 cause autosomal recessive forms of PD. For other
genes, such as the ubiquitin carboxy-terminal esterase L1, UCH-
L1, the mitochondrial serine protease Omi/HtrA2 or the synaptic
protein Synphilin-1, the association to PD is less clear and often
based on single-family reports [63–66]. The different genes
function in a number of molecular pathways that link neuronal
degeneration, as seen in PD, to protein misfolding, lysosomal
and proteasomal protein degradation as well as oxidative stress
and mitochondrial dysfunction (Fig. 2) [63,67,68].
Mutations in parkin cause the most common form of juvenile
hereditary PD. Parkin was shown to be an E3 ubiquitin-ligase
able to catalyze both poly- and monoubiquitination. Consistently,
parkin not only marks specific substrates for degradation, but it
can as well control trafficking and sorting of proteins. Moreover,
several observations made in cellular and transgenic models
suggest a role for parkin in mitochondria, a hypothesis that is
strengthened by the finding of an interaction with PINK1, both
physically and genetically [69,70]. PINK1 or the PTEN-induced
kinase 1 is a serine/threonine kinase located in mitochondria that
appears to exert a protective cellular function presumably through
phosphorylation of specific mitochondrial proteins. Although the
exact pathophysiological role of PINK1 is not yet clear, disruption
of this kinase inDrosophilawas shown to coincidewith increased
susceptibility to oxidative stress and mitochondrial morphologi-
cal defects in testis, muscle and dopaminergic neurons. These
changes ultimately result in apoptosis of muscle cells and a grad-
ual loss of dopaminergic neurons. Interestingly, the phenotypes
induced by loss of PINK1 were found to be rescued by over-
expression of parkin, while conversely, phenotypes induced by
loss of parkin were not restored by overexpression of PINK1
[70,71]. This confirms that parkin acts as an effector of PINK1 in a
linear pathway affecting mitochondrial function. Some studies
reported a physical interaction of parkin and PINK1 with DJ-1
[72,73]. DJ-1 is a member of the DJ-1/ThiJ/PfpI superfamily that
also includes the yeast protein Hsp31, which was recently shown
to confer protection against ROS [74]. The protein has been
assigned very diverse functions, but its presumed anti-oxidative
properties and chaperone activity are probably the most relevant
for PD.However, the exact physiological role ofDJ-1 in brain and
more specifically in neurodegeneration remains elusive.
Mutations in LRRK2 or dardarin are considered to be the most
common known genetic causes of sporadic PD [75]. LRRK2
contains a leucine-rich repeat, a kinase domain, a RAS domain
and aWD40 domain. This multidomain structure may explain the
pleomorphic pathology associated with the different PD-asso-
ciated mutations spread across the LRRK2 protein domains.
However, despite the vast amount of genetic data linking the
protein to PD, almost nothing is known about the exact function or
the role of this protein in the pathophysiology leading to PD.
Interestingly, mutations localized to the GTPase domain, i.e.
R1441C or the kinase domain, i.e. G2019S or I2020T, appear to
increase the kinase activity of LRRK2, favoring a gain-of-
function [76,77]. Noteworthy, overexpression of the gain-of-
functionG2019Smutant in ratswas reported to enhance apoptosis
of dopaminergic neurons [78]. Moreover, LRRK2 localizes at
membranous and vesicular structures, including mitochondria
[79] and in vitro studies further demonstrated an interaction with
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physiology.
Finally, ATP13A2, encodes for a lysosomal P-type ATPase.
PD-associated mutations in ATP13A2 appear to cause a loss-of-
function as the protein no longer localizes at the lysosome [67].
The role of this ATPase in neuropathology is not known, but theputative lysosomal dysfunction caused by loss of ATP13A2
may have important consequences for clearance of protein ag-
gregates and organelles, such as damaged mitochondria.
Although the proteins mentioned above are found in Lewy
bodies, a major constituent of these inclusions is fibrillated α-
syn. To date, three missense mutations (A30P, A53T and E46K)
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associated with familial forms of PD [81].α-Syn is a presynaptic
protein that is apparently involved in many cellular processes.
Although its exact function is still not clear, several observations
suggest a role as regulator of dopamine neurotransmission and
synaptic vesicular recycling [82]. Most recently, α-syn was
suggested to ameliorate complex assembly between plasma
membrane and vesicular SNARE proteins [83] and to have a role
in vesicle priming at a step before calcium-dependent vesicle
membrane fusion [84]. One study reported localization of α-syn
at the mitochondrial membrane [85], providing a possible direct
link between α-syn, impaired mitochondrial function and in-
creased oxidative stress as seen in PD.
α-Syn is a small protein that contains a N-terminal amphipatic
domain with six repetitions of the KTK(E/Q)GV motif, a hydro-
phobic central region and an acidic C-terminal region.Although the
protein is natively unfolded, it exhibits environmentally-induced
conformational plasticity and, as such, can assume monomeric and
oligomeric α- and β-sheet conformations and form morphologi-
cally different types of aggregates, ranging from amorphous to
amyloid-like fibrils [86]. The central hydrophobic region of α-syn
plays an important role as facilitator of fibril formation, while the
C-terminus seems to prevent fibrillation. The N-terminus also
plays an important role by allowing formation of two α-helices
upon binding to membrane microdomains, known as lipid rafts
[86,87]. These helices comprise the residues from Val3 to Val37
and from Lys45 to Thr92. The A30P mutation was shown to
prevent the unfolded to folded helix conformational change [88]
and, consistently, this mutation also disrupts the raft association
and abolishes the normal synaptic localization of α-syn [87]. The
E46K and A53T were reported not to disrupt α-helix formation
and while the former has a higher tendency to bind liposomes, the
latter shows vesicle binding kinetics similar as wild type α-syn
(WT-syn) [88]. Interestingly, the capacity of WT-syn and mutant
α-syn to bindmembranous compounds and formα-helices seems
to correlate with the propensity of these proteins to aggregate in
transfected SH-SY5Y cells [89].
α-Syn is predominantly non-phosphorylated under normal
conditions but was found to be extensively phosphorylated in α-
synucleinopathic lesions [90]. Especially phosphorylation of α-
syn at Ser129 appeared to be a dominant pathological modi-
fication inDrosophila and mice models for PD [91–94]. Also in
patients suffering from dementia with Lewy bodies or multiple
system atrophy, Ser129 phosphorylation is specifically asso-
ciated to α-syn aggregation [95,96]. Hence, Ser129 phosphor-
ylation of α-syn may result in accelerated oligomerization andFig. 2. Molecular mechanisms leading to cell death in neurons and the yeast PDmode
aggregation, obstruction of vesicular traffic and protein degradation, and mitochond
which itself coincides with ROS formation in vitro, was reported to hamper vesicle dep
and to block the UPS. Sustained induction of the UPR and impairment of the UPS in t
permeabilization leading to disrupted homeostasis of dopamine metabolism, increase
neurons. The production of ROS by the above described processes has adverse effe
mitochondrial dysfunction is known to affect the UPS. In addition, a direct physical int
proposed as alternative link explaining mitochondrial dysfunction in dopaminergic ne
shown are the different PD-associated proteins and their homologous counterparts in
Nma111. Note that in contrast to the involvement of HtrA2 and DJ-1 in PD, studies in
and a protective function of Hsp31 has not yet been demonstrated. In addition, it is nfibrillation of α-syn, a hypothesis that was further corroborated
by in vitro results [90].
Similar as for Htt in HD, there is no consensus whether
soluble protofibrils species or matured aggregates ofα-syn incite
neurotoxicity. The precise molecular events how this protein
triggers cellular degeneration also remain elusive. Deregulation
of the NMDA subtype glutamate receptor [97], malfunctioning
of the ATP-sensitive potassium channels [98], vesicle permea-
bilization and leakage of dopamine metabolites leading to oxi-
dative damage [99,100], alterations in fatty acid uptake and
metabolism [101], binding to mitochondrial membranes and
mitochondrial dysfunction [102], deregulation of ER-associated
protein degradation (ERAD) and a sustained UPR [103,104], or
malfunctioning of the UPS [105] have been suggested. In ad-
dition, aggregation ofα-syn itself was shown to generate ROS in
vitro and it was proposed that this could be sufficient to initially
trigger the PD pathology in vivo [106]. Perhaps most puzzling in
this discussion is the specificity by which α-syn induces neuro-
toxicity as exemplified by the observation that expression of
WT-syn in human fetal dopaminergic neurons induces apopto-
sis, while its expression in non-dopaminergic human cortical
neurons protects cells and increases neuronal survival [107].
3.2. Yeast models for α-syn aggregation and toxicity
When expressed in yeast, α-syn faithfully recapitulated some
of the aspects previously reported based on studies performed in
other model systems or on human brain. Consistent with their
lipid and vesicle binding properties, WT-syn and the mutant
A53T are delivered to the plasma membrane via the secretory
pathway. Once these proteins accumulate at the plasma mem-
brane they start to form inclusions. Also in yeast, inclusion
development appeared to be a nucleation-elongation process
involving the formation of small seeds at the plasma mem-
brane, which at later stages are displaced but still continue to
grow in size in the cytoplasm [108–110]. Moreover, some in-
clusionswere thioflavin-S positive, indicating that they contained
β-sheeted amyloidic fibrils [110]. Similar to observations made
in vitro [111] and cellular systems [112,113], inclusion formation
coincided with inhibition of phospholipase D, blockage of ER-
to-Golgi transport and retarded endocytosis in yeast cells
[104,108,110].
In contrast to WT-syn and A53T-syn, the A30P mutant re-
mained predominantly dispersed throughout the cytoplasm and
did not form inclusions [108–110]. This behavior is due to the
poor membrane-binding capacity of the mutant since increasingl. Shown are the main pathways involved in α-syn-mediated cell death, i.e. α-syn
rial dysfunction. In both neurons (A) and yeast cells (B), aggregation of α-syn,
endent processes, such as endocytosis and ER-to-Golgi traffic, to induce the UPR
urn trigger the production of ROS. Furthermore, α-syn protofibrils cause vesicle
d cytoplasmic dopamine levels, and enhanced oxidative stress in dopaminergic
cts on mitochondrial function, and conversely, the oxidative stress induced by
eraction ofα-syn with the outer membrane of mitochondria was demonstrated and
urons. Finally, increased oxidative stress enhances the aggregation of α-syn. Also
yeast, i.e. DJ-1 and its homologue Hsp31 as well as HtrA2 and its orthologue
yeast could not confirm a role of Nma111 in α-syn-mediated apoptotic cell death
ot yet known how LRRK2 causes neuronal loss in PD.
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allowed A30P-syn to form inclusions. Also, provision of the
necessary nuclei by WT-syn allowed inclusion formation of co-
expressed GFP-labeled A30P-syn [110]. Hence, these data
indicate that the A30P mutant is mainly defective in nucleation
because this process requires efficient membrane-binding.
Along with the failure to form inclusions under normal growth
conditions, the A30P mutant did not affect phospholipase D or
endocytosis [108,110]. Possible effects of A30P-syn expression
on ER-to-Golgi transport were not studied [104]. Interestingly, a
recent study demonstrated the A30P mutant to be targeted by
Ypp1 to the vacuole for degradation, while this was not the case
with WT-syn or the A53T mutant [114]. Whether the failure of
WT-syn and A53T-syn to bind Ypp1 and enter the vacuole di-
rectly relates to their obstructing effects on vesicular trafficking
routes and the endocytic pathway remains to be clarified.
Although initial experiments established a link between the
expression level of α-syn, inclusion formation and toxicity
[108], later reports demonstrated that α-syn toxicity is mainly
dependent on the genetic background used and that there is no
strict correlation between the presence of α-syn inclusions and
its effects on growth. As such, S. cerevisiae strains can be
loaded with α-syn inclusions but display no significant α-syn-
induced growth retardation, or conversely, show no signs of
inclusions despite a high α-syn-induced toxicity [110,115]. A
recent study analyzed the relationship between membrane af-
finity, fibrillization rate and toxicity of randomly generated
α-synmutants. Based on this analysis it was concluded thatα-syn
toxicity in yeast solely correlatedwithmembrane-binding and the
ability to form α-helices and not with the fibrillization rate of the
α-syn mutant proteins [116]. A similar conclusion can be drawn
from a study expressing α-syn in S. pombe. Unlike in budding
yeast, WT-syn and A53T-syn did not target to the plasma
membrane and despite extensive aggregation, the proteins were
nontoxic to fission yeast cells [117]. In addition, analysis of a
mutant deleted for amino acid residues in the hydrophobic central
core ofα-syn demonstrated this region to be essential to conferα-
syn toxicity [118].
3.3. Yeast-based screenings to identify cellular processes
associated with α-syn-induced toxicity and cell death
Several groups investigated which factors influence aggrega-
tion and/or toxicity of α-syn. The first genetic screening led to the
identification of 86 yeast mutants with enhanced α-syn toxicity
[53]. As could be expected, many of these mutants were affected
in lipid metabolism and vesicular transport. In addition, several
mutants were found that lacked functions involved in the
ubiquitin–proteasome system, the defense against oxidative stress
or mitochondrial activities. Interestingly, with the exception of the
mutant lacking the transcription factor Stp2, there was no overlap
in mutants retrieved from this screening and a parallel screening
performed to identify toxicity modulators for Htt, which led the
authors to suggest that distinct pathogenic mechanisms underlie
HD and PD. However, as described below, some parallels can be
drawn between the processes leading to toxicity of Htt and α-syn
expression in yeast.The link between proteasome inhibition on α-syn behavior
was confirmed, as administration of the proteasome inhibiting
drug lactacystin was reported to increase α-syn fibrillation [110]
and deletion of proteasome cap or barrel proteins was found
to enhance α-syn toxicity [115]. One study demonstrated the
converse by showing that expression of α-syn induced small
changes in proteasome composition resulting in impaired
proteasome-mediated protein degradation, an effect more severe
during the stationary phase. The same study also revealedα-syn-
mediated inhibition of protein synthesis, a phenomenon the
authors hypothesized to be linked to ER-stress [119]. ER-stress
due to a sustained UPRwas reported previously in neural models
of PD [103] andwas more recently confirmed in yeast as an early
toxicity phenotype caused by expression of WT-syn or A53T-
syn [104]. Interestingly, the search for modulators of α-syn
toxicity led to the identification of several proteins involved in
ER-to-Golgi transport, amongwhich was the RabGTPase, Ypt1.
Subsequent examination of invertebrate and mammalian models
of PD emphasized the general nature of this finding, since in
these models overexpression of Rab1, the mouse homologue of
Ypt1, protected dopaminergic neurons against α-syn toxicity
[104].
Sustained ER-stress can be a source of ROS accumulation
and oxidative stress, next to mitochondria [46]. Given the im-
portance of oxidative stress in the pathology of PD, the yeast
system was used to study in detail reciprocal effects between
oxidative stress and α-syn toxicity. Induction of free radical
generation by addition of ferrous or ferric ions was shown to
enhance fibrillation and toxicity of α-syn in yeast [110,118]. In
addition, the expression of WT-syn or mutant α-syn rendered
yeast cells more vulnerable to peroxide-induced oxidative stress.
The reason being thatα-syn expression induced the production of
ROS, externalization of phosphatidylserine and the release of
cytochrome c from mitochondria, suggesting that α-syn triggers
the apoptotic cell death program in yeast cells [120,121]. This is
similar to observationsmade in fetal dopaminergic neurons [107].
Interestingly, yeast cells can be protected from α-syn-induced
ROS accumulation by treatment with the reductant glutathione or
the heat shock response activator geldamycin, as well as by amild
heat shock or overexpression of the Hsp70 chaperone Ssa3 [120].
The underlying mechanism for protection by heat shock was not
resolved, but seems to involve binding of Ssa3 to α-syn. In ad-
dition, or alternatively, the protective heat shock-induced mech-
anism may involve Hsp104 and its co-chaperones, which as
described above for Htt, may relieve cells from ER-stress. The
effect of Hsp104 on α-syn toxicity has not been studied in yeast,
but it was shown that the protein can decrease α-syn fibrillation
in vitro [122,123]. In close connection, trehalose, which acts in
concert to Hsp104 to provide stress resistance to yeast cells, was
also found to shieldmammalian cells fromα-syn-induced toxicity
and apoptosis [50]. As mentioned, trehalose activates autophagy
synergistically to rapamycin. In yeast, rapamycin-treatment was
reported to induce clearance of α-syn aggregates [110].
Protection against α-syn-induced ROS accumulation was
also described to occur upon deletion of the yeast metacaspase,
YCA1 [120]. However, this is still controversial as others ob-
served that deletion of YCA1 did not ameliorate α-syn toxicity
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Most recently, chronological ageing experiments confirmed that
expression of α-syn enhanced apoptotic cell death in yeast
independent of Yca1 and even of Omi1/Nma111, the orthologue
of human HtrA2 [124], and this despite the clear involvement of
mitochondria [121].
The yeast system was also used in a drug discovery program
to identify compounds that would reduce α-syn toxicity. This
led to the identification of quercetin and (−)-epigallocatechin-3-
gallate, two flavonoids with metal chelating and radical scav-
enging properties [118]. Finally, it should be mentioned that co-
expression studies with other PD-associated genes, i.e. DJ-1,
parkin, PINK1, UCH-L1 or Synphilin-1, did not uncover sig-
nificant effects on α-syn toxicity in yeast [116]. Note, however,
that several of these proteins were shown to interact, suggesting
that it may be necessary to co-express these proteins simul-
taneously before effects on α-syn toxicity can be observed.
Nonetheless, enhanced toxicity was obvious when α-syn was
co-expressed with protein tau, a microtubule-associated protein
involved in Alzheimer's disease [110].
In conclusion, the yeast models presented above not only
allowed researchers to gain fundamental insight on mechanisms
of α-syn-mediated cellular degeneration (Fig. 2), but also proved
to be valid high-throughput tools for identification of neuropro-
tective agents.More complex yeast systems should be constructed
that incorporate other PD-associated genes in order to establish
possible links with α-syn aggregation and toxicity.
4. Humanized yeast models for tauopathies and
Alzheimer's disease
4.1. Introduction to tau-dependent neurodegenerative disorders
Tauopathies are multifactorial neurodegenerative disorders
clinically characterized by dementia and/or movement dysfunc-
tion. Neuropathologically, these disorders are typified by the
presence of intracellular inclusions consisting, at least in part, of
insoluble aggregated tau. More than 20 tauopathies are known
[125], among which Alzheimer's disease (AD) is the most
prevalent, with currently an estimated 12 to 17 million affected
persons and the projection that this number will double every
20 years [126]. In AD, tau-inclusions are presented as so-called
neurofibrillary tangles (NFT) with protein tau assembled into
paired-helical filaments (PHF), twisted ribbons or straight
filaments [127].
Protein tau is a microtubule-associated protein responsible
for the stabilization and spacing of microtubules and as such,
important for the regulation of axonal transport. The protein is
expressed as six isoforms derived from a single gene by
alternative mRNA splicing. These isoforms differ by one or two
additional insertions in the N-terminal domain (yielding the 0N,
1N and 2N isoforms, respectively) and by one additional copy of
the microtubule-binding repeat (yielding 3R and 4R isoforms,
respectively). The N-terminal inserts have as yet no defined
function, while the additional C-terminal insert influences
microtubule binding since tau-4R isoforms are more efficient
in stabilizing microtubules than the tau-3R isoforms.Binding of tau to microtubules is in the first instance reg-
ulated by dynamic phosphorylation via the interplay of various
protein kinases and phosphatases. The longest tau isoform, i.e.
tau-2N/4R, has 79 putative serine/threonine phosphorylation
sites, and to date phosphorylation at about 30 sites has been
reported. The study of tau phosphorylation has gained enor-
mous attention ever since the observation that protein tau in
PHF and NFT is hyper-phosphorylated [127,128]. A causal
relation between hyper-phosphorylation and aggregation of tau
is supported by in vitro experiments, showing that phosphor-
ylation of recombinant tau with purified kinases or whole brain
extracts can induce aggregation of tau. In addition, depho-
sphorylation by purified phosphatases triggers disassembly of
PHF isolated from the brain of tauopathy patients [129,130].
Nevertheless, the exact phosphorylation sites that cause aggre-
gation of tau, and the exact kinases responsible in vivo, remain
largely elusive. Recent data obtained with a Drosophila model
indicate that no single phosphorylation site plays a dominant
role in controlling tau toxicity, suggesting that different
phospho-epitopes cooperate to mediate neurodegeneration in
vivo [131,132]. An additional complication in deciphering the
triggers of tau-fiber assembly is that specific conformational
changes and truncations of protein tau also appear to be im-
portant [133]. Presumably, the conformational changes occur in
response to particular phosphorylation events, but again it is not
known which phospho-epitopes are important.
Until recently, there was no direct genetic evidence im-
plicating tau in neuronal loss and dementia. This changed with
the discovery that tau-mutations are linked to the pathology in
frontotemporal dementias (FTD). Some of these mutations
enhance splicing of exon 10 thereby altering the ratio between
the 4R and 3R tau isoforms. Other mutations affect the ability of
protein tau to interact with microtubules as could be pre-
dicted, since they alter amino acid residues in close proximity or
within the microtubule-binding repeats. Mutations located in
the amino-terminal or the carboxy-terminal region are believed
to change the conformation of tau [127,128,134]. So far, how-
ever, the effect of mutations on masking and unmasking certain
phospho-epitopes has not been studied systematically, leaving
the possibility that at least for some tau mutants the described
enhanced self-assembly could be a consequence of changes in
phosphorylation of tau.
4.2. Yeast models to study fundamentals of the tau
phosphorylation–conformation–aggregation cascade
Although there are only few studies on the expression of
human tau in yeast, the data obtained so far clearly indicate that
the yeast system robustly recapitulates crucial aspects related to
the tau pathophysiology. Indeed, human tau-3R and tau-4R
isoforms expressed in yeast acquired pathological phospho-
epitopes, assumed a pathological conformation and formed ag-
gregates [135]. Importantly, these characteristics were modulated
by the yeast protein kinases Mds1 and Pho85, the orthologues of
two of the most important mammalian tau-kinases, i.e. GSK-3β
and cdk5, respectively. Inactivation of Mds1 decreased tau phos-
phorylation at epitopes in the C-terminus. Conversely, the
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epitopes resulting in an increased conformational change and
enhanced aggregation of tau. This observation supports the hypo-
thesis that Pho85 in yeast, similar as cdk5 in mammalian neurons
[136], does not phosphorylate tau directly but acts indirectly as
negative regulator of phosphorylation and thereby conformation
and aggregation. Moreover, soluble protein tau, purified from the
pho85 mutant, spontaneously and rapidly formed twisted fila-
ments in vitro and upon further fractionation, the monomeric
hyper-phosphorylated subfraction was found to seed and ac-
celerate aggregation of protein tau isolated from a wild type yeast
strain [135]. When recombinant tau isolated from the different
yeast strain was used to monitor the physiological tau function,
the results confirmed the inverse correlation between the
phosphorylation status and the ability of the protein to bind and
stabilize microtubules. Notably, this study also included the
clinical mutant tau-P301L, which was demonstrated to actually
aggregate onto the microtubules and thereby causing their de-
formation and bundling [137].
Although wild type and mutant human tau do aggregate in
yeast cells, their expression does not affect the exponential phase
of growth. However, preliminary data indicate that the expres-
sion of human protein tau affects longevity, which may relate to
the observation that oxidative stress and mitochondrial dysfunc-
tion dramatically enhance tau aggregation in yeast (Vanhelmont
andWinderickx, unpublished data). These preliminary results fit
nicely with recently reported data obtained in Drosophila and
mice tauopathy models showing that oxidative stress and
mitochondrial dysfunction exacerbate tau-induced neurodegen-
eration [138,139].
4.3. Aβ deposits as hallmark of Alzheimer's disease
Besides intracellular aggregation of tau into NFT, the AD
brain is characterized by the occurrence of extracellular deposits
of β-amyloid (Aβ) peptides, known as amyloid or senile plaques.
Aβ peptides are generated through sequential proteolytic
cleavage of the APP precursor protein by β- and γ-secretases.
The alternative non-amyloidogenic α-secretase cleavage of APP
occurs in the middle of the Aβ region [140]. APP is an ubi-
quitously expressed type 1 transmembrane protein with putative
functions related to cell adhesion andmigration. Cleavage of APP
by β-secretase releases a soluble N-terminal ectodomain and a
membrane bound C-terminal fragment called C99. The cleavage
of C99 by γ-secretase is more variable and generates predomi-
nantly peptides Aβ1-40 or Aβ1-42, together with the remaining
C-terminal intracellular domain (AICD). The Aβ1-42 peptide
is most prone to aggregation and fibril formation and it consti-
tutes the core of the senile plaques. [141]. Aβ1-42 production
is increased in familial AD because of mutations in APP or the
γ-secretase catalytic subunits presenilin 1 and 2 [142].
While initial research focused on the extracellular aggregates,
accumulating evidence suggests that the Aβ peptide may also
exert toxicity by accumulation and aggregation within the cell.
Like most plasma membrane proteins, APP is synthesized and
translocated into the ER, further matured in the Golgi complex,
and then transported to the cell surface. A considerable amount ofAPP is subsequently internalized for recycling. In addition toAPP
processing at the neuronal plasma membrane, several groups
reported APP processing in the secretory pathway and in the
endocytic cycle [141,143,144]. How intracellular Aβ peptides
cause cellular dysfunction remains unclear, but links to endocytic
functions, the ubiquitin–proteasome activity, Ca2+ signaling, and
synaptic receptor levels have been reported [145–148]. More-
over, some studies link intracellular Aβ accumulation to the
formation of ROS, to mitochondrial damage and to apoptosis
[149–151]. Full-length APP has also been implicated in oxidative
damage and mitochondrial dysfunction because the protein can
accumulate in the mitochondria as a transmembrane protein.
Interestingly, induction of mitochondrial damage by APP is pre-
vented by cleavage of the protein by the protease HtrA2 in the
intermembrane space [152,153]. In addition, HtrA2-dependent
cleavage of APP occurs as well in the ER, suggesting a role for
HtrA2 in quality control and processing of ER-resident APP and
possibly in preventing ER-stress [154].
4.4. Yeast models for APP processing and Aβ oligomerization
Initial studies in yeast focused on the different secretases.
The first study demonstrated that APP expressed in yeast is
processed by enzymes that possess the specificity of the α-
secretases of multicellular organisms [155]. Further analysis
revealed that these α-secretases are in fact the Yap3 and Mkc7
proteases, which act on APP in the late Golgi [156]. Yeast cells
do not contain endogenous β- or γ-secretase activity, but strains
have been engineered that allow cleavage of APP by the human
β-secretase and a reconstituted γ-secretase complex [157–159].
Since the proteasome is known to remove aggregation-prone
protein derivates, a recent study analyzed processing of the C99
fragment in wild type yeast and a mutant strain lacking pro-
teasome activity. This study not only indicated a role of the
proteasome in generating longer Aβ peptides, up to 55 amino
acids, but also that the C99 fragment is processed by other
enzymes in the absence of an intact proteasome [160].
Yeast cells transformed with a vector encoding the authentic
human Aβ1-42 were reported not to produce detectable levels
of the peptide [161]. Whether this is due to toxicity of Aβ and
reflects counter selection or extremely rapid degradation of Aβ
remains to be investigated. However, the Aβ peptide can be
successfully expressed in yeast as N- or C-terminal fusion pro-
teins, and studies with such constructs indicated Aβ to lower the
growth yield and to induce a heat shock response, indicative that
the peptide induces stress in the yeast cells [161]. It would be
interesting to analyze whether these phenotypes translate into
increased oxidative stress and apoptotic cell death.
Two groups reported yeast cell-based systems that allowed
monitoring the oligomerization of Aβ-fusions [162,163]. By
the use of these systems it was confirmed that Aβ aggregation is
inhibited when point mutations are introduced in regions known
to be important for intermolecular Aβ-interaction. In addition, it
was found that Hsp104 influences Aβ oligomerization [162],
which is consistent with this chaperone playing a central role in
protein aggregation as described above. Hence, these yeast
systems appear to be very useful tools in the study of Aβ-related
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pounds affecting the aggregation process but also to decipher
the molecular pathways triggered by Aβ-aggregation.
5. Conclusions
Humanized yeast models are important tools to investigate
protein functions or cellular pathways that mediate misfolding,
aggregation and subsequent toxicity of proteins associated to
human neurodegenerative disorders. Yeast models confirmed
and further extended links to oxidative stress and mitochondrial
dysfunction and their consequences on apoptosis demonstrating
a high degree of conservation in the eukaryotic kingdom of
mechanisms involved in protein-misfolding triggered cell death
[164]. As a eukaryote, humanized yeast models provide a rele-
vant biological context, making them ideal models for identi-
fication and validation of novel – preferably ‘drug-able’ –
targets, whose modulation may affect disease biology. Also for
drug discovery efforts humanized yeast models are preferred
systems for high-throughput screening of chemical libraries, not
only because compounds are evaluated in a physiologically
relevant environment and their use is cost-effective and user
friendly, but also because these cell-based assays allow immediate
counter selection of toxic and unstable compounds as well as
compounds that cannot pass the membrane bilayer or that are
substrates for multi-drug resistance pumps [165]. Whatever the
use, studies performed in humanized yeast models may constitute
important stepping stones for further exploration in themammalian
context. Its genetic tractability and fast-growing properties allow
addressing mechanisms of a disease in an unparalleled manner
using strategies sometimes not possible in higher eukaryotic
systems. Collectively, yeast models of protein-misfolding dis-
orders contribute to the understanding of disease biology and may
facilitate strategies aimed to identify therapeutics for treating cor-
responding diseases.
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